[Ip-health] KEI Research Note 2020:2 Role of Private Sector, Governments and Charities in Funding Research and Development Related to Tocilizumab

Claire Cassedy claire.cassedy at keionline.org
Thu May 28 07:51:35 PDT 2020


https://www.keionline.org/RN-2020-2

KEI Research Note 2020:2 Role of Private Sector, Governments and Charities
in Funding Research and Development Related to Tocilizumab
Luis Gil Abinader, May 28, 2020.

>From the Introduction:

The funding of R&D for tocilizumab can be described as having three phases.
The invention and early development of tocilizumab was supported by the
government of Japan. Once the drug entered the market, most but certainly
not all of the R&D related to tocilizumab was funded by industry, including
initially by Roche or companies acquired by Roche. More recently, and
certainly as regards R&D related to COVID-19, governments have played the
leading role in funding R&D, including governments outside the United
States.

PDF:
https://www.keionline.org/wp-content/uploads/KEI_Research_Note_2020_2_Government_Funding_IP_Tocilizumab.pdf

--
Claire Cassedy
Knowledge Ecology International
1621 Connecticut Avenue NW
Suite 500
Washington, DC 20009
Tel.: 1.202.332.2670


More information about the Ip-health mailing list